West Nile virus and the safety of plasma derivatives: Verification of high safety margins, and the validity of predictions based on model virus data

Transfusion

Volumn 43, Issue 8, 2003, Pages 1023-1028

  Kreil, Thomas R ^a   Berting, Andreas ^b   Kistner, Otfried ^b   Kindermann, Johanna ^b  

^a BAXTER BIOSCIENCE   (Austria)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 INHIBITOR; HUMAN ALBUMIN; IMMUNOGLOBULIN;

ARTICLE; BIOASSAY; BLOOD COMPONENT THERAPY; HEAT TREATMENT; MODEL; NONHUMAN; PASTEURIZATION; PH; PREDICTION; PROCESS CONTROL; SAFETY; VALIDATION PROCESS; VIRUS INACTIVATION; VIRUS INFECTIVITY; VIRUS TRANSMISSION; WEST NILE FLAVIVIRUS;

BLOOD COAGULATION FACTORS; BLOOD COMPONENT TRANSFUSION; DETERGENTS; FACTOR VIII; HEAT; HUMANS; HYDROGEN-ION CONCENTRATION; IMMUNOGLOBULINS, INTRAVENOUS; MICROBIOLOGICAL TECHNIQUES; MODELS, BIOLOGICAL; SAFETY; SERUM ALBUMIN; SOLVENTS; STEAM; VIRUS INACTIVATION; WEST NILE FEVER; WEST NILE VIRUS;

EID: 0042430604     PISSN: 00411132     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1537-2995.2003.00496.x     Document Type: Article

References (9)

1. Petersen LR, Roehrig JT. West Nile virus: a reemerging global pathogen. Emerg Infect Dis 2001;7:611.
2. West Nile virus update: current case count (Internet). Atlanta (GA): CDC; updated 2003 Apr 16. Available from: http://www.cdc.gov/od/oc/media/wncount.htm
3. Investigations of West Nile virus infections in recipients of blood transfusions. Morb Mortal Wkly Rep 2002;51/43:973.
4. Committee for Proprietary Medicinal Products (CPMP). Note for guidance on virus validation studies: the design, contribution and interpretation of studies validating the inactivation and removal of viruses (Internet). CPMP/BWP/268/95CPMP/BWP/268/95. London: The European Agency for the Evaluation of Medicinal Products; 1996 Feb 14. Available from: http://www.emea.eu.int/pdfs/human/bwp/026895en.pdf
5. Center for Biologics Evaluation and Research. Information about West Nile virus and blood safety (Internet). Rockville (MD): The Center; 2002 Oct 3. Available from: http://www.fda.gov/cber/safety/wnvbld.htm
6. Beasley DWC, Li L, Suderman MT, Barrett ADT. Mouse neuroinvasive phenotype of West Nile Virus strains varies depending on virus genotype. Virology 2002;296:17.
7. Southam CM, Moore AE. Induced virus infections in man by the Egypt isolates of West Nile virus. Am J Trop Med Hyg 1954;31:724.
8. Horowitz B, Lazo A, Grossberg H, et al. Virus inactivation by solvent/detergent treatment and the manufacture of SD-plasma. Vox Sang 1998;74(Suppl 1):203.
9. Gollins SW, Porterfield JS. The uncoating and infectivity of the flavivirus West Nile on interaction with cells: effects of pH and ammonium chloride. J Gen Virol 1968;67:1941.